Amneal Pharmaceuticals (AMRX) Enterprise Value (2017 - 2026)

Amneal Pharmaceuticals' Enterprise Value history runs 10 years deep, the most recent figure standing at -$4.7 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 107.17% year-over-year to -$4.7 million in Q1 2026; TTM through Mar 2026 was -$4.7 million, a 107.17% decrease from a year earlier, with the FY2025 full-year figure at -$282.6 million, down 519.96% from the prior year.
• Enterprise Value grew to -$4.7 million in Q1 2026 per AMRX's latest filing, from -$282.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at $66.0 million in Q1 2025 and bottomed at -$282.6 million in Q4 2025.
• The 5-year median for Enterprise Value is $10.4 million (2022), against an average of -$16.3 million.
• Across the five-year window, Enterprise Value sank 1231.64% in 2023 and soared 13052.99% in 2025, its largest moves.
• Year by year, Enterprise Value stood at $15.7 million in 2022, then sank by 420.1% to -$50.2 million in 2023, then gained by 9.3% to -$45.6 million in 2024, then sank by 519.96% to -$282.6 million in 2025, then jumped by 98.33% to -$4.7 million in 2026.
• Per Business Quant, the three latest AMRX Enterprise Value figures stand at -$4.7 million (Q1 2026), -$282.6 million (Q4 2025), and $33.1 million (Q3 2025).